Literature DB >> 24021304

Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use.

Alberto E Tozzi1, Edwin J Asturias, Madhava Ram Balakrishnan, Neal A Halsey, Barbara Law, Patrick L F Zuber.   

Abstract

Serious illnesses or even deaths may rarely occur after childhood vaccinations. Public health programs are faced with great challenges to establish if the events presenting after the administration of a vaccine are due to other conditions, and hence a coincidental presentation, rather than caused by the administered vaccines. Given its priority, the Global Advisory Committee for Vaccine Safety (GACVS) commissioned a group of experts to review the previously published World Health Organization (WHO) Adverse Event Following Immunization (AEFI) causality assessment methodology and aide-memoire, and to develop a standardized and user friendly tool to assist health care personnel in the processing and interpretation of data on individual events, and to assess the causality after AEFIs. We describe a tool developed for causality assessment of individual AEFIs that includes: (a) an eligibility component for the assessment that reviews the diagnosis associated with the event and identifies the administered vaccines; (b) a checklist that systematically guides users to gather available information to feed a decision algorithm; and (c) a decision support algorithm that assists the assessors to come to a classification of the individual AEFI. Final classification generated by the process includes four categories in which the event is either: (1) consistent; (2) inconsistent; or (3) indeterminate with respect of causal association; or (4) unclassifiable. Subcategories are identified to assist assessors in resulting public health decisions that can be used for action. This proposed tool should support the classification of AEFI cases in a standardized, transparent manner and to collect essential information during AEFI investigation. The algorithm should provide countries and health officials at the global level with an instrument to respond to vaccine safety alerts, and support the education, research and policy decisions on immunization safety.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2013        PMID: 24021304     DOI: 10.1016/j.vaccine.2013.08.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

2.  Comparison of the tolerability of newly introduced childhood vaccines in the Netherlands.

Authors:  Jeanet M Kemmeren; Nicoline At van der Maas; Hester E de Melker
Journal:  Eur J Pediatr       Date:  2017-04-20       Impact factor: 3.183

3.  Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.

Authors:  Natalie L McCarthy; Julianne Gee; Lakshmi Sukumaran; Eric Weintraub; Jonathan Duffy; Elyse O Kharbanda; Roger Baxter; Stephanie Irving; Jennifer King; Matthew F Daley; Rulin Hechter; Michael M McNeil
Journal:  Pediatrics       Date:  2016-02-01       Impact factor: 7.124

4.  COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.

Authors:  Francesco Ferrara; Carolina Mancaniello; Alessia Varriale; Sarah Sorrentino; Andrea Zovi; Eduardo Nava; Ugo Trama; Mariarosaria Boccellino; Antonio Vitiello
Journal:  Clin Drug Investig       Date:  2022-10-23       Impact factor: 3.580

Review 5.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

Review 6.  Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Authors:  Edwin J Asturias; Melinda Wharton; Robert Pless; Noni E MacDonald; Robert T Chen; Nicholas Andrews; David Salisbury; Alexander N Dodoo; Kenneth Hartigan-Go; Patrick L F Zuber
Journal:  Vaccine       Date:  2016-05-16       Impact factor: 3.641

7.  International Consensus (ICON): allergic reactions to vaccines.

Authors:  Stephen C Dreskin; Neal A Halsey; John M Kelso; Robert A Wood; Donna S Hummell; Kathryn M Edwards; Jean-Christoph Caubet; Renata J M Engler; Michael S Gold; Claude Ponvert; Pascal Demoly; Mario Sanchez-Borges; Antonella Muraro; James T Li; Menachem Rottem; Lanny J Rosenwasser
Journal:  World Allergy Organ J       Date:  2016-09-16       Impact factor: 4.084

8.  Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2.

Authors:  Mina Psichogiou; Michael Samarkos; Nikolaos Mikos; Angelos Hatzakis
Journal:  Vaccines (Basel)       Date:  2021-06-01

9.  Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.

Authors:  Fabien V K Diomandé; Téné M Yaméogo; Kirsten S Vannice; Marie-Pierre Preziosi; Simonetta Viviani; Claude-Roger Ouandaogo; Modibo Keita; Mamoudou H Djingarey; Nehemie Mbakuliyemo; Bartholomew Dicky Akanmori; Samba O Sow; Patrick L F Zuber
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

Review 10.  The clinical development process for a novel preventive vaccine: An overview.

Authors:  K Singh; S Mehta
Journal:  J Postgrad Med       Date:  2016 Jan-Mar       Impact factor: 1.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.